EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
16.75 USD
3.65%
Market Closed
Updated:
Apr 29, 2024
EyePoint Pharmaceuticals Inc
Operating Income
|
EyePoint Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Operating Income
-$75.1m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-18%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$4.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is EyePoint Pharmaceuticals Inc's Operating Income?
Operating Income
-75.1m
USD
-75.1m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Operating Income amounts to -75.1m USD.
What is EyePoint Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-18%
-18%
Over the last year, the Operating Income growth was 5%. The average annual Operating Income growth rates for EyePoint Pharmaceuticals Inc have been -27% over the past three years , -14% over the past five years , and -18% over the past ten years .
You don't have any saved screeners yet
